Replies to post #1920 on Ocera Therapeutics fka OCRX

[DewDiligence]

205-of-230 STOP-HE patients enrolled—completion of enrollment expected in 4Q16:

#msg-125240812

[DewDiligence]

OCRX had $32.5M cash at 9/30/16 (a reduction of only $2.9M since 6/30/16 thanks to use of the ATM facility); guidance for year-end cash remains $22-26M, implying a projected cash burn of $8.5M ± $2M during 4Q16:

http://finance.yahoo.com/news/ocera-therapeutics-reports-third-quarter-130500471.html